In comparison, HER2 status was less likely to be positive in mucinous carcinoma (60.9%, p < 0.0001), invasive papillary carcinoma (4.9%, p = 0.0008), and mixed invasive carcinoma (NOS) and lobular carcinoma (3.0%, p = 0.0006), when compared with invasive carcinoma (NOS) (19.7%). This evidence concerns the gene ERBB2 and breast lobular carcinoma.